Radical Therapy of Hypercholesterolaemia and Atherosclerosis

  • G. R. Thompson
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 58)


Before describing the various methods available for treating severe hypercholesterolaemia and the accompanying atherosclerosis it is first necessary to discuss the nature of the problem and define the objectives to be achieved. It seems appropriate to start by considering the pathology of fatal coronary heart disease (CHD), as described by Roberts.1 His autopsy findings can be summarised as follows: Atherosclerotic lesions involve the entire coronary tree, usually with 2 or 3 major branches critically stenosed, i.e., narrowed by more than 75%; the main stem of the left coronary artery is critically stenosed in 25% of cases, this lesion always being accompanied by severe triple vessel disease; critical stenoses are always due to complicated plaques, of which fibrous tissue is the major component but approximately 25% is lipid. These features suggest that fatal CHD is usually associated with severe but not necessarily irreversible atherosclerosis.


Serum Cholesterol Primary Biliary Cirrhosis Plasma Exchange Familial Hypercholesterolaemia Portacaval Shunt 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    W. C. Roberts, The status of the coronary arteries in fatal ischemic heart disease, Cardiovasc. Clinics 7: 1 (1975).Google Scholar
  2. 2.
    M. Feinleib, W. B. Kannel, C. G. Tedeschi, T. K. Landau, and R. J. Garrison, The relation of antemortem characteristics to cardiovascular findings at necropsy, Atherosclerosis 34: 145 (1979).PubMedCrossRefGoogle Scholar
  3. 3.
    G. Rose, Detection of high coronary risk, Postgrad. Med. J. 52: 452 (1976).PubMedCrossRefGoogle Scholar
  4. 4.
    W. L. Proudfit, E. K. Shirey, and F. M. Sones, Selective cine coronary arteriography. Correlation with clinical findings in 1000 patients, Circulation 33: 901 (1966).PubMedGoogle Scholar
  5. 5.
    R. G. Murray, A. Tweddel, J. L. H. C. Third, I. Hutton, W. S. Hillis, A. R. Lorimer, and T. D. V. Lawrie, Relation between extent of coronary artery disease and severity of hyperlipoproteinaemia, Brit. Heart J. 37: 1205 (1975).PubMedCrossRefGoogle Scholar
  6. 6.
    D. C. Banks, E. B. Raftery, and S. Oram, Clinical significance of the coronary arteriogram, Brit. Heart J. 33: 863 (1971).PubMedCrossRefGoogle Scholar
  7. 7.
    A. M. Gotto, G. A. Gorry, J. R. Thompson, J. S. Cole, R. Trost, D. Yeshuron, and M. E. Debakey, Relationship between plasma lipid concentrations and coronary artery disease in 496 patients, Circulation 56: 875 (1977).PubMedGoogle Scholar
  8. 8.
    M. H. Frick, D. Dahlen, K. Berg, M. Valle, and P. Hekali, Serum lipids in angiographically assessed coronary atherosclerosis, Chest 73: 62 (1978).PubMedCrossRefGoogle Scholar
  9. 9.
    P. J. Jenkins, R. W. Harper, and P. J. Nestel, Severity of coronary atherosclerosis related to lipoprotein concentration, Brit. Med. J. 2: 388 (1978).PubMedCrossRefGoogle Scholar
  10. 10.
    V. Fuster, R. L. Frye, D. C. Connolly, M. A. Danielson, L. R. Elveback, and L. T. Kurland, Arteriographic patterns early in the onset of the coronary syndromes, Brit. Heart J. 37: 1250 (1975).PubMedCrossRefGoogle Scholar
  11. 11.
    R. A. Heinle, R. I. Levy, D. S. Frederickson, and R. Gorlin, Lipid and carbohydrate abnormalities in patients with angiographically documented coronary artery disease, Amer. J. Cardiol. 24: 178 (1969).PubMedCrossRefGoogle Scholar
  12. 12.
    C. E. Bemis, R. Gorlin, H. G. Kemp, and M. V. Herman, Progression of coronary artery disease, Circulation 47: 455 (1973).PubMedGoogle Scholar
  13. 13.
    D. T. Nash, G. Gensini, H. Simon, T. Arno, and S. D. Nash, The Erysicthon Syndrome. Progression of coronary atherosclerosis and dietary hyperlipidemia, Circulation 56: 363 (1977).PubMedGoogle Scholar
  14. 14.
    G. R. Thompson, Familial hypercholesterolaemia, in:“The Lipoprotein Molecule,” H. Peeters, ed., Plenum Press, New York (1978).Google Scholar
  15. 15.
    J. M. Allen, G. R. Thompson, N. B. Myant, R. Steiner, and C.M. Oakley, Cardiovascular complications of homozygous familial hypercholesterolaemia, Brit. Heart J. 44: 361 (1980).PubMedCrossRefGoogle Scholar
  16. 16.
    J. Slack, Risk of ischaemic heart disease in familial hyperlipoproteinaemic states, Lancet 2: 1380 (1969).PubMedCrossRefGoogle Scholar
  17. 17.
    A. Bloch, R. E. Dinsmore, and R. S. Lees, Coronary arteriographic findings in type-II and type-IV hyperlipoproteinaemia, Lancet 1: 928 (1976).PubMedCrossRefGoogle Scholar
  18. 18.
    D. D. Sugrue, G. R. Thompson, C. M. Oakley, I. M. Trayner, and R. E. Steiner, Contrasting patterns of coronary atherosclerosis in normocholesterolaemic smokers and patients with familial hypercholesterolaemia, Brit. Med. J. in press (1981).Google Scholar
  19. 19.
    J. V. Talano, P. J. Scanlon, W. R. Meadows, M. Kahn, R. Pifarre, and R. M. Gunnar, Influence of surgery on survival in 145 patients with left main coronary artery disease, Circulation 52 (Suppl.1): 105 (1975).Google Scholar
  20. 20.
    K. Detre, M. L. Murphy, and H. Hultgren, Effect of coronary bypass surgery on longevity in high and low risk patients, Lancet 2: 1243 (1977).PubMedCrossRefGoogle Scholar
  21. 21.
    J. Crittin, D. D. Waters, P. Theroux, and H. F. Mizgala, Left main coronary artery stenosis in young patients, Chest 76: 508 (1979).PubMedCrossRefGoogle Scholar
  22. 22.
    J. J. Barboriak, K. Pintar, and M.E. Korns, Atherosclerosis in aortocoronary vein grafts, Lancet 2: 621 (1974).PubMedCrossRefGoogle Scholar
  23. 23.
    J. J. Barboriak, G. E. Batayias, K. Pintar, and M. E. Korns, Pathological changes in surgically removed aortocoronary vein grafts, Ann. Thor. Surg. 21: 524 (1976).CrossRefGoogle Scholar
  24. 24.
    J. T. Lie, G. M. Lawrie, and G. C. Morris, Aortocoronary bypass saphenous vein graft atherosclerosis. Anatomic study of 99 vein grafts from normal and hyperlipoproteinemic patients up to 75 months post-operatively, Amer. J. Cardiol. 40: 906 (1977).PubMedCrossRefGoogle Scholar
  25. 25.
    M. L. Armstrong, E. D. Warner, and W. E. Connor, Regression of coronary atheromatosis in Rhesus monkeys, Circulation Res. 27: 59 (1970).PubMedGoogle Scholar
  26. 26.
    M. L. Armstrong, and M. B. Megan, Lipid depletion in atheromatous coronary arteries in Rhesus monkeys after regression diets, Circulation Res. 30: 675 (1972).PubMedGoogle Scholar
  27. 27.
    A. Daoud, J. Jarmolych, J. M. Augustyn, K. E. Fritz, J. K. Singh, and K. T. Lee, Regression of advanced atherosclerosis in swine, Arch. Pathol. Lab. Med. 100: 372 (1976).PubMedGoogle Scholar
  28. 28.
    R. G. Depalma, S. Koletsky, E. M. Bellon, and W. Insull, Failure of regression of atherosclerosis in dogs with moderate cholesterolemia, Atherosclerosis 27: 297 (1977).PubMedCrossRefGoogle Scholar
  29. 29.
    P. T. Kuo, K. Hayase, J. B. Kostis, and A. E. Moreyra, Use of combined diet and colestipol in long-term (7–72 years) treatment of patients with type II hyperlipoproteinemia, Circulation 59: 199 (1979).PubMedGoogle Scholar
  30. 30.
    T. E. Starzl, H. P. Chase, C. W. Putnam, and K. A. Porter, Portacaval shunt in hyperlipoproteinaemia, Lancet 2: 940 (1973).PubMedCrossRefGoogle Scholar
  31. 31.
    T. E. Starzl, H. P. Chase, C. W. Putnam, and J. J. Nora, Follow-up of patient with portacaval shunt for the treatment of hyperlipidaemia, Lancet 2: 714 (1974).PubMedCrossRefGoogle Scholar
  32. 32.
    T. E. Starzl, H. P. Chase, C. W. Putnam, J. J. Nora, R. H. Fennell, and K. A. Porter, Portacaval shunt in hyperlipidaemia, Lancet 2: 1263 (1974).PubMedCrossRefGoogle Scholar
  33. 33.
    T. E. Starzl, L. Koep, and R. Weil, Portacaval shunt for type II hyperlipidemia, in “Atherosclerosis V,” A. M. Gotto, L. C. Smith, and B. Allen, ed., Springer-Verlag, New York (1980).Google Scholar
  34. 34.
    E. A. Stein, J. Pettifor, C. Mieny, K. W. Heimann, I. Spitz, I. Bersohn, I. Saaron, and M. Dinner, Portacaval shunt in four patients with homozygous hypercholesterolaemia, Lancet 1: 832 (1975).PubMedCrossRefGoogle Scholar
  35. 35.
    E. A. Stein, and C. J. Glueck, Homozygous hypercholesterolaemia: treatment by portacaval shunt, in: “Atherosclerosis V,” A. M. Gotto, L. C. Smith, and B. Allen, ed., Springer-Verlag, New York (1980).Google Scholar
  36. 36.
    O. Faergeman, J. Gormsen, and H. Meinertz, Anti-platelet drugs and portacaval anastomosis for homozygous hypercholesterolaemia, Lancet 2: 1416 (1976).PubMedCrossRefGoogle Scholar
  37. 37.
    J. T. Coyle, M. Z. Schwartz, A. T. Marubbio, R. L. Varco, and H. Buchwald, The effect of portacaval shunt on plasma lipids and tissue cholesterol synthesis in the dog, Surgery 80: 54 (1976).PubMedGoogle Scholar
  38. 38.
    T. E. Starzl, K. Watanabe, K. A. Porter, and C. W. Putnam, Effects of insulin, glucagon and insulin/glucagon infusions on liver morphology and cell division after complete porta-caval shunt in dogs, Lancet 1: 821 (1976).PubMedCrossRefGoogle Scholar
  39. 39.
    H. P. Chase, and T. Morris, Cholesterol metabolism following portacaval shunt in the pig, Atherosclerosis 24: 141 (1976).PubMedCrossRefGoogle Scholar
  40. 40.
    T. E. Carew, R. P. Saik, K. H. Johansen, C. A. Dennis, and D. Steinberg, Low density and high density lipoprotein turnover following portacaval shunting in swine, J. Lipid Res. 17: 441 (1976).PubMedGoogle Scholar
  41. 41.
    A. C. Nestruck, S. Lussier-Cacan, M. Bergseth, M. Bidallier, J. Davignon, and Y. L. Marcel, The effect of portacaval shunt on plasma lipids and lipoproteins in swine, Biochim. Biophys. Acta 488: 43 (1977).PubMedGoogle Scholar
  42. 42.
    D. W. Bilheimer, J. L. Goldstein, S. M. Grundy, and M. S. Brown, Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in patient with homozygous familial hypercholesterolemia, J. Clin. Invest. 56: 1420 (1975).PubMedCrossRefGoogle Scholar
  43. 43.
    A. K. Soutar, N. B. Myant, and G. R. Thompson, Simultaneous measurement of apolipoprotein B turnover in very-low-and low-density lipoproteins in familial hypercholesterolaemia, Atherosclerosis 28: 247 (1977).PubMedCrossRefGoogle Scholar
  44. 44.
    J.-L. DeGennes, R. Touraine, B. Maunand, J. Truffert, and P. Laudat, Formes homozygotes cutaneo-tendineuses de xanthomatose hypercholestérolémique dans une observation familiale exemplaire. Essai de plasmaphérése â titre de traitment héroique. Bull. Mem. Soc. Hop. Paris 118: 1377 (1967).Google Scholar
  45. 45.
    L. A. Turnberg, M. P. Mahoney, M. H. Gleeson, C. B. Freeman, and A. H. Gowenlock, Plasmaphoresis and plasma exchange in the treatment of hyperlipaemía and xanthomatous neuropathy in patients with primary biliary cirrhosis, Gut 13: 976 (1972).PubMedCrossRefGoogle Scholar
  46. 46.
    G. R. Thompson, R. Lowenthal, and N. B. Myant, Plasma exchange in the management of homozygous familial hypercholesterolaemia, Lancet 1: 1208 (1975).PubMedCrossRefGoogle Scholar
  47. 47.
    G. R. Thompson, N. B. Myant, D. Kilpatrick, C. M. Oakley, M. J. Raphael, and R. E. Steiner, Assessment of long-term plasma exchange for familial hypercholesterolaemia, Brit. Heart J. 43: 680 (1980).PubMedCrossRefGoogle Scholar
  48. 48.
    G. Thompson, N. Myant, C. Oakley, R. Steiner, and R. Sapsford, Combined medico-surgical strategy for severe familial hypercholesterolaemia, in: “Atherosclerosis V,” A. M. Gotto, L. C. Smith,and B. Allen, ed., Springer-Verlag, New York (1980).Google Scholar
  49. 49.
    G. R. Thompson, Plasma exchange for hypercholesterolaemia, Lancet 1: 1246 (1981).PubMedCrossRefGoogle Scholar
  50. 50.
    G. M. B. Berger, J. L. Miller, F. Bonnici, H. S. Joffe, and D. W. Dubovsky, Continuous flow plasma exchange in the treatment of homozygous familial hypercholesterolemia, Amer. J. Med. 65: 243 (1978).PubMedCrossRefGoogle Scholar
  51. 51.
    L. A. Simons, J. C. Gibson, J. P. Isbíster, and J. C. Biggs, The effects of plasma exchange on cholesterol metabolism, Atherosclerosis 31: 195 (1978).PubMedCrossRefGoogle Scholar
  52. 52.
    M. E. E. King, J. L. Breslow, and R. S. Lees, Plasma-exchange therapy of homozygous familial hypercholesterolemia, New Engl. J. Med. 301: 1457 (1980).CrossRefGoogle Scholar
  53. 53.
    J. L. Witzum, J. C. Williams, R. Ostlund, L. Sherman, G. Siccard, and G. Schonfeld, Successful plasmapheresis in a 4 year old child with homozygous familial hypercholesterolemia, J. Pediat. 97: 615 (1980).CrossRefGoogle Scholar
  54. 54.
    G. M. B. Berger, F. Bonnici, H. S. Joffe, and D. W. Dubovsky, Plasma exchange in the treatment of familial hypercholesterolemia, in: “Atherosclerosis V,” A. M. Gotto, L. C. Smith, and B. Allen, ed., Springer-Verlag, New York (1980).Google Scholar
  55. 55.
    E. A. Stein, C. J. Glueck, A. Wesselman, E. R. Owens, S. Nichols, and P. Vink, Repetitive intermittnet flow plasma exchange in patients with severe hypercholesterolemia, Atherosclerosis 38: 149 (1981).PubMedCrossRefGoogle Scholar
  56. 56.
    L. A. Simons, J. J. Morgan, J.C. Gibson, J. P. Isbister, and J. C. Biggs, Regression of atherosclerosis, Atherosclerosis 35: 345 (1980).PubMedCrossRefGoogle Scholar
  57. 57.
    G. R. Thompson, and N. B. Myant, Regression of atherosclerosis, Atherosclerosis 35: 347 (1980).PubMedCrossRefGoogle Scholar
  58. 58.
    G. R. Thompson, Plasma exchange for hypercholesterolaemia: a therapeutic mode and investigative tool, Plasma Ther. 1: 5 (1980).Google Scholar
  59. 59.
    G. R. Thompson, Long-term plasma exchange in severe familial hypercholesterolaemia, in: “Proceedings of the Workshop on Therapeutic Plasma and Cytapheresis,” in press (198-).Google Scholar
  60. 60.
    G. R. Thompson, Plasma exchange in hyperlipidemia, in: “Therapeutic Plasma Exchange,” H. Gurland, V. Heinze, and H. A. Lee, ed., Springer-Verlag, Berlin Heidelberg (1981).Google Scholar
  61. 61.
    P-J. Lupien, S. Moorjani, and J. Awad, A new approach to the management of familial hypercholesterolaemia: removal of plasma cholesterol based on the principle of affinity chromatography, Lancet 1: 1261 (1976).PubMedCrossRefGoogle Scholar
  62. 62.
    B. Graisely, M. Cloarec, S. Salmon, J. Polonovski, C. Polonovski, J. M. Delacotte, J. Gardent, J. Cavalier, D. Vergoz, and C. Salmon, Extracorporeal plasma therapy for homozygous familial hypercholesterolaemia, Lancet 2: 1147 (1980).PubMedCrossRefGoogle Scholar
  63. 63.
    W. Stoffel, and T. Demant, Selective removal of apolipoprotein B-containing serum lipoproteins from blood plasma, Proc. Nat. Acad. Sci. USA 78: 611 (1981).PubMedCrossRefGoogle Scholar
  64. 64.
    H. Buchwald, Lowering of cholesterol absorption and blood levels by ileal exclusion, Circulation 29: 713 (1964).PubMedGoogle Scholar
  65. 65.
    H. Buchwald, R. B. Moore, and R. L. Varco, Partial ileal bypass: a test of the lipid-atherosclerosis hypothesis, in: “Atherosclerosis V,” A. M. Gotto, L. C. Smith, and B. Allen, ed., Springer-Verlag, New York (1980).Google Scholar
  66. 66.
    H. Buchwald, R. B. Moore, and R. L. Varco, Ten years clinical experience with partial ileal bypass in management of the hyperlipidaemias, Ann. Surg. 180: 384 (1974).PubMedCrossRefGoogle Scholar
  67. 67.
    R. B. Moore, H. Buchwald, R. L. Varco, et al., The effect of partial ileal bypass on plasma lipoproteins, Circulation 62: 469 (1980).PubMedGoogle Scholar
  68. 68.
    H. Buchwald, R. B. Moore, G. B. Lee, I. D. Frantz, and R. L. Varco, Treatment of hypercholesterolemia.Combined dietary, surgical, and bile-salt binding resin therapy, Arch. Surg 97: 275 (1968).CrossRefGoogle Scholar
  69. 69.
    E. H. Strisower, R. M. Kradjian, A. V. Nichols, E. Coggiola, and J. Tsai, Effect of ileal bypass on serum lipoproteins in essential hypercholesterolemia, J. Atheroscl. Res. 8: 525 (1968).CrossRefGoogle Scholar
  70. 70.
    T. A. Miettinen, and M. Lempinen, Ileal bypass operation in familial hypercholesterolemia, Scand. J. Clin. Lab. Invest. Suppl. 113: 55 (1970).Google Scholar
  71. 71.
    T. A. Miettinen, and M. Lempinen, Cholestyramine and ileal bypass in the treatment of familial hypercholesterolaemia, Eur. J. Clin. Invest. 7: 509 (1977).PubMedCrossRefGoogle Scholar
  72. 72.
    D. Russell, V. Fritz, C. Mieny, D. Mendelsohn, B. I. Joffe, and H. C. Seftel, Treatment of familial hypercholesterolaemia by partial ileal bypass, S. A. Med. J. 55: 237 (1979).Google Scholar
  73. 73.
    F. A. Spengel, A. Jadhav, R. G. M. Duffield, C. B. Wood, and G. R. Thompson, Cholesterol reduction in familial hypercholesterolaemia: superiority of partial ileal bypass over cholestyramine, Lancet in press (1981).Google Scholar
  74. 74.
    R. B. Moore, J. M. Long, J. P. Matts, K. Amplatz, R. L. Varco, H. Buchwald, and The Posch Group, Plasma lipoproteins and coronary arteriography in subjects in the program on the surgical control of the hyperlipidemias. Preliminary report, Atherosclerosis 32: 101 (1979).PubMedCrossRefGoogle Scholar
  75. 75.
    L. Knight, R. Scheibel, K. Amplatz, R. L. Varco, and H. Buchwald, Radiographic appraisal of the Minnesota partial ileal bypass study, Surg. Forum 23: 141 (1972).PubMedGoogle Scholar
  76. 76.
    R. R. Henderson, and G. G. Rowe, The progression of coronary atherosclerotic disease as assessed by cine-coronary angiography, Amer. Heart J. 86: 165 (1973).PubMedCrossRefGoogle Scholar
  77. 77.
    J. A. Davis, I. D. A. Johnston, C. D. Moutafis, and N. B. Myant, Ileal bypass in hypercholesterolaemia, Lancet 2: 971 (1966).CrossRefGoogle Scholar
  78. 78.
    S. M. Grundy, E. H. Ahrens, and G. Salen, Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism, J. Lab. Clin. Med. 78: 94 (1971).PubMedGoogle Scholar
  79. 79.
    H. Buchwald, R. B. Moore, I. D. Frantz, and R. L. Varco, Cholesterol reduction by partial ileal bypass in a paediatric population, Surgery 68: 1101 (1970).PubMedGoogle Scholar
  80. 80.
    J. F. Balfour, and R. Kim, Homozygous type II hyperlipoproteinemia treatment. Partial ileal bypass in two children, J. Amer. Med. Ass. 227: 1145 (1974).CrossRefGoogle Scholar
  81. 81.
    T. A. Miettinen, Comparison of cholestyramine,ileal by-pass and portocaval shunt in the treatment of familial hypercholesterolemia, in: “Atherosclerosis V,” A. M. Gotto, L. C. Smith, and B. Allen, ed., Springer-Verlag, New York (1980).Google Scholar
  82. 82.
    G. R. Thompson, and A. M. Gotto, Ileal bypass in the treatment of hyperlipoproteinaemia, Lancet 2: 35 (1973).PubMedCrossRefGoogle Scholar
  83. 83.
    H. Buchwald, and R. L. Varco, Partial ileal bypass for hypercholesterolemia and atherosclerosis, Surg. Gynaecol. Obstet. 124: 1231 (1967).Google Scholar
  84. 84.
    R. B. Moore, I. D. Frantz, and H. Buchwald, Changes in cholesterol pool size, turnover rate, and fecal bile acid and sterol excretion after partial ileal bypass in hypercholesteremic patients, Surgery 65: 98 (1969).PubMedGoogle Scholar
  85. 85.
    C. D. Moutafis, N. B. Myant, and S. Tabaqchali, The metabolism of cholesterol after resection or by-pass of the lower small intestine, Clin. Sci. 35: 537 (1968).PubMedGoogle Scholar
  86. 86.
    J. Shepherd, C. J. Packard, S. Bicker, T. D. V. Lawrie, and H. G. Morgan, Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism, New Engl. J. Med. 302: 1219 (1980).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1983

Authors and Affiliations

  • G. R. Thompson
    • 1
  1. 1.Medical Research Council Lipid Metabolism UnitHammersmith HospitalLondonUK

Personalised recommendations